Baku:Democratic Republic of the Congo The World Health Organisation (WHO) has recommended the inclusion of two new vaccine candidates in the ongoing clinical trials to address the Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC).

According to Emirates News Agency, the two vaccines, ChAdOx1 BDBV, developed by the University of Oxford in collaboration with the Serum Institute of India, and Moderna's mRNA-1469, mark the first vaccines created specifically to target the Bundibugyo virus.

The DRC Ministry of Health has confirmed that the death toll from the virus has climbed to 5,163, with the total number of confirmed cases reaching 10,603 as of November 2nd. This represents a case fatality rate of 48.7 percent.